COMPASS PATHWAYS PLC (CMPS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 112.89M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 12.98M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -181.76M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $112.89M | (m) | $12.98M | $-181.76M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $114.04M | (m) | $12.55M | $-172.32M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $118.44M | (m) | $13.59M | $-179.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $120.67M | (m) | $15.23M | $-181.50M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $126.27M | (m) | $17.00M | $-188.86M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $125.02M | (m) | $18.32M | $-189.25M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $119.04M | (m) | $19.52M | $-178.21M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $114.04M | (m) | $19.22M | $-168.20M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $102.64M | (m) | $18.70M | $-154.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $93.38M | (m) | $18.34M | $-143.70M | $3.30M | (m) | (m) | -43.52× | Reported |
| 2023-12-31 | $87.52M | (m) | $17.28M | $-136.92M | $2.20M | (m) | (m) | -62.12× | Reported |
| 2023-09-30 | $80.17M | (m) | $16.39M | $-130.71M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $72.62M | (m) | $15.45M | $-122.18M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $68.73M | (m) | $14.07M | $-116.77M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $65.05M | (m) | $13.12M | $-110.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $58.85M | (m) | $12.59M | $-106.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $57.07M | (m) | $11.38M | $-102.77M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $52.51M | (m) | $10.10M | $-95.04M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $44.03M | (m) | $8.64M | $-83.22M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $34.98M | (m) | $7.22M | $-66.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $29.66M | (m) | $10.15M | $-58.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $23.37M | (m) | $17.98M | $-51.39M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $12.56M | (m) | $3.25M | $-21.18M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |